Joep de Bruijne

Assistant Professor - medical

Strategic program(s):

Contact

jbruijn7@umcutrecht.nl

Pure profile

Research groups

Primary Liver Tumors research group

Research aim

To improve surveillance, diagnostics, treatment, and outcome for patients with primary liver tumors (hepatocellular carcinoma and cholangiocarcinoma) by interdisciplinary and (inter-)national collaborative research

Go to group

Recent publications

All publications

Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA) Niek Wijnen, Rutger C G Bruijnen, Evert-Jan P A Vonken, Hugo W A M de Jong, Joep de Bruijne, Guus M Bol, Jeroen Hagendoorn, Martijn P W Intven, Maarten L J Smits
Cancers, 2024, vol. 16

Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor Ablation Maarten L.J. Smits, Rutger C.G. Bruijnen, Philip Tetteroo, Evert jan P.A. Vonken, Martijn R. Meijerink, Jeroen Hagendoorn, Joep de Bruijne, Warner Prevoo
Cardiovascular and Interventional Radiology, 2023, vol. 46, p.1365-1374

Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma M. H. Van Der Ree, A. J. Van Der Meer, A. C. Van Nuenen, J. De Bruijne, S. Ottosen, H. L. Janssen, N. A. Kootstra, H. W. Reesink
Alimentary Pharmacology and Therapeutics, 2016, vol. 43, p.102-113

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients Meike H. Van Der Ree, Adriaan J. Van Der Meer, Joep De Bruijne, Raoel Maan, Andre Van Vliet, Tania M. Welzel, Stefan Zeuzem, Eric J. Lawitz, Maribel Rodriguez-Torres, Viera Kupcova, Alcija Wiercinska-Drapalo, Michael R. Hodges, Harry L.A. Janssen, Hendrik W. Reesink
Antiviral Research, 2014, vol. 111, p.53-59

MicroRNAs Meike H.Der Van Ree, Joep De Bruijne, Neeltje A. Kootstra, Peter L.M. Jansen, Hendrik W. Reesink
Antiviral Therapy, 2014, vol. 19, p.533-541

Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up D. M. Hotho, J. De Bruijne, M. Spaan, M. A. Treitel, A. Boonstra, R. J. De Knegt, H. L.A. Janssen, H. W. Reesink
Journal of Viral Hepatitis, 2013, vol. 20, p.e78-e81